Feedback from U.S. Food and Drug Administration (FDA) supports advancement into a pivotal Phase 3 trial and a 505(b)(2) regulatory pathway Phase 3 SURPASS-IPF trial remains on track to be initiated by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback